A Phase I, Randomised, Double-blind, Placebo-controlled Study in Patients With Amyotrophic Lateral Sclerosis to Further Assess the Safety and Tolerability of Intracerebroventricular Administration of sNN0029 Infusion Solution
Phase of Trial: Phase I
Latest Information Update: 12 Feb 2016
Price : $35 *
At a glance
- Drugs Telbermin (Primary)
- Indications Amyotrophic lateral sclerosis
- Focus Adverse reactions
- Sponsors Newron Sweden AB
- 26 Jan 2016 Status changed from recruiting to discontinued as per ClinicalTrials.gov record.
- 08 Oct 2014 Planned End Date changed from 1 Jan 2015 to 1 Sep 2015 as reported by ClinicalTrials.gov.
- 08 Oct 2014 Planned primary completion date changed to 1 Sep 2015 as reported by ClinicalTrials.gov.